Current version snapshot

FDA-approved↗↗↗↗Metabolic↗

Current · version 4: Liraglutide↗

Related names recorded in this version: Saxenda, Victoza↗↗

A GLP-1 receptor agonist approved by FDA as Victoza and Saxenda, with approved generic versions. Large randomized trials support its weight-management and cardiovascular evidence.↗↗↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the liraglutide label and the Drugs@FDA approval records, and added the LEADER trial report and FDA’s April 2026 503B proposal. 137

What this version reported

The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.↗↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗↗

Reader guide in this version

Key takeaway

Liraglutide is a lab-made version of the gut hormone GLP-1. Drugs@FDA lists it as the active ingredient of Victoza, first approved in 2010, and Saxenda, first approved in 2014, and FDA has since approved generic versions.1,3,4,5 The liraglutide weight-management label cited here covers long-term weight reduction in adults, and in children aged 12 and older with obesity and body weight above 60 kilograms.1 Large randomized trials support it, including three 56-week weight trials described in the label and the LEADER cardiovascular outcomes trial of 9,340 adults with type 2 diabetes.1,7 The label carries a boxed warning about thyroid C-cell tumors seen in rats and mice; whether liraglutide causes them in humans is unknown.1

At a glance

What it is
A GLP-1 receptor agonist. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.1
FDA status
FDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.1,3,4,5
Human evidence
Large randomized, placebo-controlled trials: weight trials described in the label and the published LEADER cardiovascular outcomes trial.1,7
Evidence strength
Large randomized human trials

What is liraglutide?

Liraglutide is a lab-made peptide modeled on GLP-1, a hormone released by the gut. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.1

Drugs@FDA lists two Novo Nordisk brands, Victoza and Saxenda, and approved generic applications from other companies.3,4,5

How does liraglutide work?

The label states that liraglutide binds to and activates the GLP-1 receptor, like the natural hormone, and that GLP-1 is a physiological regulator of appetite and calorie intake.1

According to the label, natural GLP-1 is broken down within minutes, while liraglutide resists that breakdown and lasts much longer in the body. In rats, it activated brain regions that regulate appetite, though the label says the specific regions behind its effect on appetite were not identified.1

What do human studies show?

The label describes three 56-week randomized, placebo-controlled weight trials. In the largest, of 3,731 adults without type 2 diabetes, average weight fell 7.4% with liraglutide and 3% with placebo, and 62.3% and 34.4%, respectively, lost at least 5% of their body weight.1

In the 56-week trials, the label reports that 27% of the liraglutide groups and 35% of the placebo groups stopped the study drug, and about 10% and 4%, respectively, stopped because of an adverse reaction.1

In LEADER, 9,340 adults with type 2 diabetes and high cardiovascular risk were followed for a median of 3.8 years. The main cardiovascular outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, a reported hazard ratio of 0.87.7

LEADER was funded by its sponsor, and its findings apply to adults with type 2 diabetes at high cardiovascular risk who were receiving standard care.7

What the evidence base contains

  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 3,731 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes.1
  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 635 adults with type 2 diabetes and overweight or obesity.1
  • Large randomized human trial LEADER, a double-blind, randomized, placebo-controlled cardiovascular outcomes trial in 9,340 adults with type 2 diabetes and high cardiovascular risk, published in The New England Journal of Medicine.7
  • Controlled human trial A 56-week randomized, double-blind, placebo-controlled trial in 251 adolescents aged 12 to 17 with obesity (NCT02918279).1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is liraglutide FDA-approved?

Yes. Drugs@FDA records list Victoza’s original approval on January 25, 2010 and Saxenda’s on December 23, 2014. Generic liraglutide applications have also been approved, the first on December 23, 2024.3,4,5

The label cited here, for a generic liraglutide weight-management product (DailyMed SPL version 6, published July 14, 2026), states that it is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults and children aged 12 and older with obesity and body weight above 60 kilograms, and in adults with overweight and at least one weight-related condition.1

The label states that safety and effectiveness in children with type 2 diabetes have not been established. Uses of other liraglutide products, such as Victoza, are set by their own labels, which are not cited here.1

The label carries a boxed warning: liraglutide caused thyroid C-cell tumors in rats and mice, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1

Other warnings in the label cover acute pancreatitis, gallbladder disease, low blood sugar, increased heart rate, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions and aspiration during anesthesia or deep sedation.1

In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines. The label cited here lists that warning as removed in February 2026.1,2

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.6

Timeline

  1. FDA approves Victoza, the first liraglutide product, according to Drugs@FDA.3
  2. FDA approves Saxenda, according to Drugs@FDA.4
  3. LEADER cardiovascular outcomes results are published.7
  4. FDA approves the first generic liraglutide application in the records cited here.5
  5. FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.2
  6. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.6
  7. DailyMed publishes the liraglutide label version cited on this page.1

What is still unknown?

Whether liraglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1

Whether LEADER’s cardiovascular result applies to people at lower cardiovascular risk or without type 2 diabetes, who were not studied in that trial.7

How benefits and harms change after treatment stops and over longer follow-up than the trials reviewed here.7

Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.6

Sources for this version

  1. 1
    Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  3. 3
    Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  7. 7
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026